| Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma C Fiorentini, S Grisanti, D Cosentini, A Abate, E Rossini, A Berruti, ... Journal of Oncology 2019, 2019 | 43 | 2019 |
| Correction: Sigala et al. A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma. Cells 2022 … S Sigala, C Bothou, D Penton, A Abate, M Peitzsch, D Cosentini, ... Cells 12 (18), 2274, 2023 | 22* | 2023 |
| Cytotoxic effect of trabectedin in human adrenocortical carcinoma cell lines and primary cells A Abate, E Rossini, SA Bonini, M Fragni, D Cosentini, GAM Tiberio, ... Cancers 12 (4), 928, 2020 | 18 | 2020 |
| Cytotoxic effect of progesterone, tamoxifen and their combination in experimental cell models of human adrenocortical cancer E Rossini, M Tamburello, A Abate, S Beretta, C Hantel, F Bono, S Grisanti, ... Frontiers in Endocrinology 12, 669426, 2021 | 17 | 2021 |
| Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures S Grisanti, D Cosentini, M Laganà, A Abate, E Rossini, S Sigala, A Berruti Current Opinion in Endocrine and Metabolic Research 8, 80-87, 2019 | 16 | 2019 |
| An update on adrenocortical cell lines of human origin S Sigala, E Rossini, A Abate, M Tamburello, SR Bornstein, C Hantel Endocrine 77 (3), 432-437, 2022 | 14 | 2022 |
| In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures☆ M Fragni, LPP Lopez, E Rossini, A Abate, D Cosentini, V Salvi, S Vezzoli, ... Molecular and cellular endocrinology 498, 110585, 2019 | 14 | 2019 |
| Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? V Cremaschi, A Abate, D Cosentini, S Grisanti, E Rossini, M Laganà, ... Expert Opinion on Pharmacotherapy 23 (12), 1413-1424, 2022 | 12 | 2022 |
| Estrogen-like effect of mitotane explained by its agonist activity on estrogen receptor-α E Rossini, E Giacopuzzi, F Gangemi, M Tamburello, D Cosentini, A Abate, ... Biomedicines 9 (6), 681, 2021 | 12 | 2021 |
| Ribociclib cytotoxicity alone or combined with progesterone and/or mitotane in in vitro adrenocortical carcinoma cells A Abate, E Rossini, M Tamburello, M Laganà, D Cosentini, S Grisanti, ... Endocrinology 163 (2), bqab248, 2022 | 10 | 2022 |
| Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen A Turla, M Laganà, S Grisanti, A Abate, VD Ferrari, V Cremaschi, S Sigala, ... Endocrine 77 (3), 438-443, 2022 | 7 | 2022 |
| Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma M Laganà, S Grisanti, R Ambrosini, D Cosentini, A Abate, M Zamparini, ... ESMO open 7 (2), 100422, 2022 | 7 | 2022 |
| Cisplatin cytotoxicity in human testicular germ cell tumor cell lines is enhanced by the CDK4/6 inhibitor palbociclib E Rossini, V Bosatta, A Abate, M Fragni, V Salvi, RM Basnet, D Zizioli, ... Clinical Genitourinary Cancer 19 (4), 316-324, 2021 | 7 | 2021 |
| Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines M Tamburello, A Abate, E Rossini, RM Basnet, D Zizioli, D Cosentini, ... International Journal of Molecular Sciences 24 (7), 6829, 2023 | 5 | 2023 |
| Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models A Abate, M Tamburello, E Rossini, RM Basnet, G Ribaudo, A Gianoncelli, ... Endocrine-Related Cancer 30 (2), 2023 | 4 | 2023 |
| Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: A preclinical study T Savarese, A Abate, RM Basnet, L Lorini, C Gurizzan, M Tomasoni, ... Scientific Reports 12 (1), 9951, 2022 | 4 | 2022 |
| Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable … A Turla, M Laganà, A Abate, V Cremaschi, M Zamparini, M Chittò, ... Cancers 15 (18), 4491, 2023 | 3 | 2023 |
| 36P Progesterone and trabectedin activity in preclinical cell models of adrenocortical carcinoma A Abate, M Tamburello, RM Basnet, D Zizioli, M Laganà, D Cosentini, ... ESMO Open 9, 2024 | | 2024 |
| 23P Preclinical evaluation of targeted agents alone or combined with chemotherapy in the adenoid cystic carcinoma cells A Abate, T Savarese, RM Basnet, L Lorini, C Gurizzan, M Tomasoni, ... ESMO Open 9, 2024 | | 2024 |
| 35P ABACUS trial: Abiraterone acetate in the management of Cushing’s syndrome associated to adrenocortical carcinoma D Cosentini, S Puglisi, S Grisanti, V Basile, M Laganà, VD Ferrari, A Abate, ... ESMO Open 9, 2024 | | 2024 |
